[1] FENG J,HU L H,LU J,et al.Diagnostic value of BRCA1 and p16 gene methylation in sporadic breast cancer[J].CJC,2009,28(4): 1-6.
[2] TANG L C,YIN W J,DI G H,et al.Unfavorable clinic pathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young chinese breast cancer patients[J].Breast Cancer Res Treat,2010,122: 95-104.
[3] 韩璐璐,刘剑仑.调控细胞周期的乳腺癌抑癌基因的研究进展[J].中国癌症防治杂志,2011,4(3): 339-340.
[4] KWONG A,CHEUNG P,CHAN S,et al.Breast cancer in chinese women younger than age 40: are they different from their older counterparts?[J].World J Surg,2008,32: 2554-2561.
[5] HINSHELWOOD R A,MELKI J R,HUSCHTSCHA L I,et al.Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning[J].Hum Mol Genet,2009,16(28): 3098-3109.
[6] VALLIAN S,SEDAGHAT M,NASSIRI I,et al.Methylation status of p16INK4A tumor suppressor gene in Iranian patients with sporadic breast cancer[J].J Cancer Res Clin Oncol,2009,135: 991-996.
[7] ZHAO L,YU Z J,LI Y N,et al.Clinical implications of ERb methylation on sporadic breast cancers in Chinese women[J].Med Oncol,2012,29: 1569-1575.
[8] 张,郑荣生.乳腺癌患者血清中p16基因甲基化状态的研究[J].临床肿瘤学杂志,2010,15(5): 399-402.
[9] MENG H T,PETER G S,JING N,et al.DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer(WEB)Study[J].Breast Cancer Res Treat,2009,114: 559-568.
[10] 曾谷清,康颖,高天舒,等.乳腺癌组织中P16蛋白的表达与细胞增殖的关系[J].中国现代医学杂志,2007,6(17): 650-653.
[11] THOMAS M,JÖRG F,CHELSEE A H.Analysing DNA methylation using bisulphite pyrosequencing[M].USA: Humana Press,2011: 33-53.
[12] SHEN S X,DAHUI Q.Pyrosequencing data analysis software: a useful tool for EGFR,KRAS,and BRAF mutation analysis[J].Diagn Pathol,2012,7: 56.
[13] 魏茂富,杨延莉,刘镜文.P16在乳腺癌及乳腺腺病中的表达及其临床意义[J].临床探讨,2010,48(7): 138-139.
[14] 秦洪真,汪敏,李席如,等.乳腺癌患者CerbB-2表达和组织激素受体、淋巴结转移的关系[J].现代医学,2009,37(5): 336-338.
[15] 蒋文英,桑剑锋,苏磊,等.乳腺癌新辅助化疗疗效及其判断方法[J].现代医学,2011,39(2): 237-240. |